Executive Summary
Gastroenterology Benefit-Risk Analysis
Gastroenterology benefit-risk assessment is driven by the expanding biologic and small molecule landscape for inflammatory bowel disease, the need for gut-selectivity safety differentiation, and hepatotoxicity monitoring across GI therapeutics. ArcaScience's GI BRA methodology integrates endoscopic and histologic endpoints alongside systemic safety assessments for the full spectrum of IBD, liver, and functional GI therapies.
The platform's GI-specific models cover TNF inhibitor class effects, integrin inhibitor gut-selectivity, JAK inhibitor safety in UC, S1P receptor modulator PML risk assessment, and comprehensive liver safety monitoring (Hy's Law, DILI patterns). GI models achieve 92% accuracy in hepatotoxicity signal classification and automated endoscopic response categorization across Mayo and SES-CD scoring systems.
Key Takeaways
4 Gastroenterology-Specific Innovations
Endoscopic Response Analytics
Automated endoscopic scoring integration (Mayo, SES-CD, Rutgeerts) with mucosal healing assessment and histologic remission correlation analysis.
Gut-Selectivity Assessment
Comparative safety profiling of gut-selective (vedolizumab) versus systemic immunosuppressive therapies, quantifying systemic infection risk differential.
DILI Monitoring
Automated drug-induced liver injury detection using Hy's Law criteria, RUCAM scoring, and pattern recognition for hepatocellular, cholestatic, and mixed DILI patterns.
IBD Class Comparison
Quantitative comparative BRA across TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors, JAK inhibitors, and S1P modulators for UC and Crohn's disease.
Whitepaper Contents
8 Comprehensive Chapters
Download
Get the Full Gastroenterology BRA Methodology Guide
Complete the form below to receive the document via email.
Related Resources